Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Muir KW, Ford GA, Ford I, Wardlaw JM, et al. Lancet Neurol 2024;23:1087-1096.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Muir KW, Ford GA, Ford I, Wardlaw JM, et al. Tenecteplase versus alteplase for acute stroke within 4.5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial. Lancet Neurol 2024;23:1087-1096.
PMID: 39424558